Yasushi Fukuda

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi et al. · Clinical Cancer Research · 2020 · 233 citations

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka et al. · Lung Cancer · 2018 · 142 citations

Medicine, Clinical Trials, Immune Checkpoint Inhibitor +6

Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy

Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka et al. · Journal of Thoracic Oncology · 2018 · 116 citations

Medicine, Cancer Management, Nivolumab Monotherapy +6

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <i>EGFR</i> -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda et al. · Clinical Cancer Research · 2021 · 70 citations · Full text

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Metastatic Sites, High Pd-l1 Expression, Medicine +7